Foghorn Therapeutics (FHTX) Income Statement: Revenue & Earnings

Foghorn Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Foghorn Therapeutics Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	22.60	34.16	19.23	1.32	0.43
Cost of Revenue	0.00	109.69	105.62	80.33	57.72
Gross Profit	22.60	-75.53	19.23	-79.01	-57.29
Operating Expenses
Research & Development	94.53	109.69	105.62	80.33	0.00
Selling, General & Administrative	28.36	32.37	30.75	21.73	11.25
Operating Expenses	125.29	142.06	136.37	21.73	11.25
Operating Income	-102.68	-107.91	-117.14	-100.73	-68.53
Other Income/Expense
Interest Income	11.90	10.88	5.68	0.06	0.10
Interest Expense	0.00	0.00	0.00	-1.91	-0.98
Other Income/Expense	16.06	2.83	2.58	2.49	0.83
Income
Income Before Tax	-86.62	-94.20	-108.88	-101.32	-68.80
Income Tax Expense	0.00	4.23	0.00	0.00	0.00
Net Income	-86.62	-98.43	-108.88	-101.32	-68.80
Net Income - Continuous Operations	-86.62	-98.43	-108.88	-101.32	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-97.17	-104.46	-113.82	-97.51	-67.20
EBIT	-86.60	-107.91	-117.14	-100.73	-68.53
Depreciation & Amortization	3.12	3.45	3.30	3.23	1.33
Earnings Per Share
Basic EPS	-2.00	-2.00	-3.00	-3.00	-6.00
Diluted EPS	-2.00	-2.00	-3.00	-3.00	-6.00
Basic Shares Outstanding	54.90	41.97	41.59	37.17	11.05
Diluted Shares Outstanding	54.90	41.97	41.59	37.17	11.05